Quantcast

East and Central Asia

Breast cancer patients testing Enzychem’s cheaper Mosedipimod, hopes for FDA’s approval

Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.

Posted in Approval, Asia, news, Regions | Tagged , , , | Leave a comment

Sanovas expands in China, $75 million in capitalization

Sanovas, Inc., a Life Science technology company will establish a venture capital fund and Innovation Center at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences to advance the company’s innovations and sales in China.

Posted in Approval, Asia, news | Tagged , | Leave a comment

Grünenthal buys AstraZeneca’s migraines drug

AstraZeneca has signed an agreement with Grünenthal for the global rights to Zomig (zolmitriptan), the drug indicated for the acute treatment of migraines and cluster headaches, outside Japan.

Posted in Asia, news, North America, Regions | Tagged , , | Leave a comment

Asia to be drug delivery technology market fastest-growing region

Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.

Posted in Approval, Asia, Europe, news, North America, Regions | Tagged , | Leave a comment

Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test

Oxford BioDynamics’s subsidiary Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited, to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.

Posted in Asia, Europe, news, Regions | Tagged , , , , | Leave a comment

South Korea fines Novartis $49 million over kickbacks, suspends insurance payment

South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs, and also suspended insurance coverage for some of its drugs.

Posted in Asia, Europe, news | Tagged , | Leave a comment

China’s Biostar Pharmaceuticals reports $5.7M loss in 2016

Biostar Pharmaceuticals, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, has reported its financial results for the year ended December 31, 2016.

Posted in Asia, news, Regions | Tagged | Leave a comment

Novartis in-licenses dry eye therapeutic ECF843 worldwide

Novartis said Thursday it has exercised an option to in-license ECF843 for ophthalmic indications worldwide excepot of Europe, without revealing financial and other terms of this transaction.

Posted in Africa, Approval, Asia, Australia, Latin America, Middle East and North Africa, news, North America, Regions | Tagged , , | Leave a comment

Sanofi’s partner JHL Biotech accepted for clinical trial in China

JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).

Posted in Approval, Asia, news, Regions | Tagged , , , , , , | Leave a comment

Shire’s attention deficit hyperactivity disorder drug to sell in Japan

Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.

Posted in Approval, Asia, Europe, news, Regions | Tagged , , , | Leave a comment